Y. Pommier, M. O’Connor, J. D. de Bono
Oct 26, 2016
Citations
26
Influential Citations
512
Citations
Quality indicators
Journal
Science Translational Medicine
Abstract
Understanding the mechanism of action of PARP inhibitors is key to optimizing their clinical use and effectiveness. Poly(ADP-ribose) polymerase (PARP) inhibitors are the first DNA damage response targeted agents approved for cancer therapy. Here, we focus on their molecular mechanism of action by PARP “trapping” and what this means for both clinical monotherapy and combination with chemotherapeutic agents.